Rituximab vs intravenous methylprednisolone
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
- RR 0.35 [0.02, 8.08]1 study · 31 participantsVery low